Affymetrix, a part of Thermo Fisher Scientific, is a pioneer in microarray technology and a leader in genomics analysis. Affymetrix develops and provides innovative technologies that enable multiplex and parallel analysis of biological systems at the cell, protein, and gene level, facilitating the rapid translation of results into biology for a better world.
Our extensive portfolio of translational and clinical solutions enables scientists and clinicians to rapidly translate their research into understanding underlying disease mechanisms, identifying biomarkers for personalized medicine, creating novel molecular diagnostic tests, and improving genetic marker-assisted breeding programs in agriculture for human health and wellness.
We strive to provide leadership and support, partnering with our customers in their quest to translate biological knowledge into clinical application and routine use. We are proud to be part of Thermo Fisher Scientific, helping to advance our mission to enable our customers to make the world healthier, cleaner, and safer.
Affymetrix' GeneChip® technology was invented in the late 1980's by a team of scientists led by Stephen P.A. Fodor, PhD. The theory behind their work was revolutionary - a notion that semiconductor manufacturing techniques could be united with advances in combinatorial chemistry to build vast amounts of biological data on a small glass chip. This technology became the basis of a new company, Affymetrix, formed as a division of Affymax, N.V. in 1991. Affymetrix began operating independently in 1992 and commercial sales of the GeneChip® system for research use commenced in 1994. Affymetrix completed its initial public offering in June 1996 and since then completed a number of acquisitions to strengthen its portfolio and serve customers:
Genetic MicroSystems, Inc.
Affymetrix acquired Genetic MicroSystems, Inc., a privately held Massachusetts instrumentation company specializing in DNA array technology, in February 2000.
Affymetrix acquired Neomorphic, Inc., a privately held computational genomics company, in October 2000.
ParAllele BioScience Inc.
Affymetrix acquired ParAllele BioScience, Inc., a privately held provider of highly scalable technology for comprehensive genetic studies, in October 2005.
Affymetrix acquired USB Corporation, a privately held Cleveland, Ohio-based company that provides an extensive line of molecular biology and biochemical reagent products, in December 2007. The acquisition included Anatrace, Inc., a wholly owned subsidiary that provides membrane protein extraction and purification products.
True Materials Inc.
Affymetrix acquired True Materials Inc., a privately held San Francisco-based company that has developed a technology capable of multiplexing up to 10,000 markers, in July 2008.
In November 2008, Affymetrix acquired Panomics Inc., a privately held Fremont, California-based company that offers a powerful suite of assay products for a wide variety of low- to mid-plex genetic, protein, and cellular analysis applications.
In June 2012, Affymetrix acquired eBioscience Holding Company, Inc., a privately held San Diego, California-based company that is an industry leader in flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics. eBioscience offers one of the world's largest selections of antibodies, ELISAs, and proteins for life science research and diagnostics.
Eureka Genomics Corporation
In May 2015, Affymetrix acquired substantially all the assets of Hercules, CA-based Eureka Genomics® Corporation. Eureka Genomics is a developer of cost-effective, low- to mid-plex, high throughput genotyping assays that use common next-generation sequencing (NGS) platforms for signal readout. These assays enable the detection of hundreds to thousands of genetic markers which are increasingly in demand for routine crop and animal agrigenomics testing.
Through these acquisitions and internal development, Affymetrix has provided innovative technologies that enable multiplex and parallel analysis of biological systems at the cell, protein, and gene level, facilitating the rapid translation of results into biology for a better world.
In April 2016, Thermo Fisher Scientific acquired Affymetrix, strengthening its leadership in biosciences and creating new opportunities in integrated genetic analysis workflows.